Department of Neurology, Clinical Medical College of Dali University, Dali, China.
Eur Rev Med Pharmacol Sci. 2022 Mar;26(5):1500-1507. doi: 10.26355/eurrev_202203_28214.
The aim of the current study was to investigate the association between brain-derived neurotrophic factor (BDNF) and generalized anxiety disorder (GAD).
A total of sixty male adult Wistar rats with similar body weight and age were randomly divided into 3 groups the blank control group (CON, n=20), the saline control group (SAL, n=20), and the combined medication group (Deanxit +fluoxetine, DF, n=20), then rats in group SAL and group DF were prepared for model of anxiety disorder for 14 days. The body weight, center-retention time (CRT) and square-crossover number per unit time (SCN) were compared during modeling to define the anxiety of rats on day 1, day 7 and day 14; the BDNF mRNA in brain were detected by RT-PCR and the protein of BDNF in brain were detected by immunohistochemistry before and after intervention. The body weight, CRT and SCN in group SAL and DF after modeling were decreased with time compared with CON (p<0.05). The rats were taken euthanasia after 14 days, the BDNF mRNA showed significant decrease in SAL group (0.58±0.07) compared with group CON (2.87±0.23), while in DF group (1.76±0.21), the BDNF mRNA were higher than SAL group but lower than CON (p<0.05); the BDNF positive cells in group CON was highest (90%), then was group DF (75%) and group SAL was the lowest (35%).
The changes in the indexes of the rats among different groups before and after modeling showed that after modeling, the body weights of the rats in group SAL and group DF were lower than group CON, the CRT decreased, and the SCN increased. The differences were statistically significant (p < 0.05), indicating that the combined medication (Qilixin + fluoxetine) can improve anxiety symptoms (body weight, CRT, and SCN).
Anti-anxiety drugs (Deanxit+fluoxetine) can improve anxiety symptoms of rats and increase the expressions of BDNF mRNA and protein in rat brain cells. Anxiolytic drugs (Deanxit+fluoxetine) may achieve the treatment of anxiety disorders through improving the 5-HT nervous system and the expressions of BDNF mRNA and protein. BDNF can be used as a biochemical indicator for the diagnosis and efficacy evaluation of GAD.
本研究旨在探讨脑源性神经营养因子（BDNF）与广泛性焦虑障碍（GAD）之间的关系。
将 60 只雄性成年 Wistar 大鼠随机分为 3 组，空白对照组（CON，n=20）、生理盐水对照组（SAL，n=20）和联合用药组（Deanxit+氟西汀，DF，n=20）。然后，SAL 组和 DF 组大鼠制备焦虑症模型 14 天。在建模期间比较大鼠的体重、中心保留时间（CRT）和单位时间内的正方形交叉次数（SCN），以确定大鼠在第 1、第 7 和第 14 天的焦虑程度；采用 RT-PCR 检测脑内 BDNF mRNA，免疫组织化学法检测脑内 BDNF 蛋白。与 CON 组相比，SAL 组和 DF 组建模后体重、CRT 和 SCN 随时间逐渐降低（p<0.05）。14 天后处死大鼠，SAL 组 BDNF mRNA 显著降低（0.58±0.07），CON 组为 2.87±0.23，DF 组为 1.76±0.21，DF 组高于 SAL 组，但低于 CON 组（p<0.05）；CON 组 BDNF 阳性细胞最高（90%），其次是 DF 组（75%），SAL 组最低（35%）。
不同组大鼠建模前后各指标变化显示，SAL 组和 DF 组大鼠建模后体重低于 CON 组，CRT 降低，SCN 增加，差异有统计学意义（p<0.05），提示联合用药（Qilixin+氟西汀）可改善焦虑症状（体重、CRT、SCN）。
抗焦虑药物（Deanxit+氟西汀）可改善焦虑大鼠的焦虑症状，增加大鼠脑细胞 BDNF mRNA 和蛋白的表达。抗焦虑药物（Deanxit+氟西汀）可能通过改善 5-HT 神经系统和 BDNF mRNA 和蛋白的表达来治疗焦虑障碍。BDNF 可作为 GAD 诊断和疗效评估的生化指标。
